About Us
We are a non-profit, membership-led, multistakeholder and multidisciplinary partnership. We bring together patient organizations, medical associations, scientific societies, umbrella coalitions, psychedelic foundations, and for-profit sector.
The Greek word ‘parea’ means to be in the company of friends or to do something together. In Greek culture, parea is a venue for the growth of the human spirit and the exploration of ideas to enrich our quality of life.
Those values guide our joint efforts to change perceptions about psychedelic-assisted therapies, raise awareness on the scientific advances and, ultimately, bring better brain health to European citizens.
By combining and streamlining the knowledge and expertise of PAREA members, we bring comprehensive advice and guidance to EU policymakers – whilst delivering value to society in the process.
Our Mission
Safe, modern, and ethically responsible integration of psychedelic therapies into European mainstream health services, where those novel treatments are an additional therapeutic option, accessible and affordable for all, as registered and reimbursed medical treatments.
In achieving our mission, we will:
Strive to change perceptions at the EU-level regarding psychedelic medicines by promoting evidence-based information.
Raise awareness, provide evidence-based policy recommendations, and accelerate scientific and policy responses for psychedelic therapies.
Advocate for stepping up EU efforts to thoroughly assess the medical benefits of psychedelic compounds, as well as to better understand and mitigate associated risks.
Foster more EU-funded research to meaningfully increase the scientific and clinical evidence supporting the safe use of these compounds as medicines.
Advocate for a coherent and harmonized EU policy and regulatory framework.
Support the development of measures to prepare healthcare systems for the adoption of psychedelic therapies.
Our Objectives
Foster research
to increase clinical evidence supporting the safe use of psychedelic compounds as therapies, and ease the barriers to doing research with these compounds
Decrease stigma
by education and promoting evidence-based information and debunking myths
Promote meaningful engagement and safeguard optimal care and safety for patients
by facilitating engagement across all drug development phases and accompanying psychotherapeutic treatment practices, while upholding high-quality standards of care.
Increase collaboration
between civil society, scientists and policymakers
Build capacity at the healthcare-systems level
by identifying bottlenecks and capacity constraints to deliver at scale and by ensuring that necessary European infrastructure and competencies are developed in advance
Ensure equitable, timely, affordable, safe, and legal access
to psychedelic treatments when they become available
Support drug reform
to promote health-oriented, harm-reducing drug policies based on scientific evidence and human rights
Contribute to a diverse and equitable psychedelic ecosystem
taking into account issues such as sustainability, reciprocity, diversity, fair IP management, open science as well as ethical and constructive business models.